Is there a particular program that is of interest to you, or is it mainly their platform that you like?
They seem to have a deep pipeline but I'm not sure why MACK should merit a ~$600M market cap. One could point to several innovative oncology-focused biotechs with similarly deep pipelines trading for half that valuation IMHO.
Their lead program isn't bi-specific or multi-specific antibody. Their mAb against ErbB3 is probably the most advanced antibody for this particular target. So, it is more the platform for bi-specific/multi-specific I am interested in at the moment. I was interested in MITI's bi-specific many years ago when very few were, MEDX's immunotherapy when very few were. So MACK is the one similar to those two I am out there at the moment. MACK is well below IPO price now.
News 
Market Data 
Discover 
